☆ 4.2 Meeting Abstract

Phase 1 Study of CA-4948, a Novel Inhibitor of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) in Patients with R/R Non-Hodgkin Lymphoma (NHL)

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)

Journal

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

Volume 19, Issue -, Pages S256-S257

Publisher

CIG MEDIA GROUP, LP

DOI: 10.1016/j.clml.2019.07.168

Keywords

ABCL; aggressive B-cell lymphoma; IRAK4; MYD88; DLBCL; TLR; NHL

Categories

Oncology Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Cell Biology

The IRAK4 scaffold integrates TLR4-driven TRIF and MYD88 signaling pathways

Milton Pereira, Danielle F. Durso, Clare E. Bryant, Evelyn A. Kurt-Jones, Neal Silverman, Douglas T. Golenbock, Ricardo T. Gazzinelli

Summary: This study examines the importance of IRAK proteins in TLR4 activation and confirms the essential role of IRAK4 kinase activity in MYD88 signaling. It also reveals the crucial role of the IRAK4 scaffold in integrating MYD88 and TRIF in TLR4 signaling.

CELL REPORTS (2022)

Add to Collection

Article Pharmacology & Pharmacy

A novel IRAK4/PIM1 inhibitor ameliorates rheumatoid arthritis and lymphoid malignancy by blocking the TLR/MYD88-mediated NF-KB pathway

Sae-Bom Yoon, Hyowon Hong, Hee-Jong Lim, Ji Hye Choi, Yoon Pyo Choi, Seong Wook Seo, Hyuk Woo Lee, Chong Hak Chae, Woo-Kyu Park, Hyun Young Kim, Daeyoung Jeong, Tran Quang De, Chang-Seon Myung, Heeyeong Cho

Summary: IRAK4 plays a key role in the TLR/MYD88 signaling pathway and is highly activated in rheumatoid arthritis tissues and ABC-DLBCL. IRAK4 activation promotes B-cell proliferation and lymphoma aggressiveness. We developed a dual IRAK4/PIM1 inhibitor, KIC-0101, which effectively suppresses the NF-KB pathway and proinflammatory cytokine induction in vitro and in vivo. KIC-0101 shows promising results in treating autoimmune diseases and ibrutinib-resistant B-cell lymphomas.

ACTA PHARMACEUTICA SINICA B (2023)

Add to Collection

Article Microbiology

Cbl-b negatively regulates TLR/MyD88-mediated anti-Toxoplasma gondii immunity

Haixia Wei, Shuizhen Wu, Liying Mai, Lili Yang, Weihao Zou, Hongjuan Peng

Summary: This study reveals the important role of Cbl-b in Toxoplasma gondii infection. Knockout of Cbl-b significantly inhibits T. gondii proliferation and reduces parasitic burden. In Cbl-b KO mice, the proportion of B cells increases, while the proportion of macrophages decreases. The levels of interferon-gamma and interleukin-6 in the serum are higher, indicating that Cbl-b negatively regulates the host's immune response through the TLR/MyD88 pathway.

MICROBIOLOGY SPECTRUM (2023)

Add to Collection

Article Biochemical Research Methods

Direct MYD88(L265P) gene detection for diffuse large B-cell lymphoma (DLBCL) via a miniaturised CRISPR/dCas9-based sensing chip

Weihan Sun, Wei Guo, Zhiyi Liu, Sennan Qiao, Ziming Wang, Jiayu Wang, Lingxuan Qu, Liang Shan, Fei Sun, Shuping Xu, Ou Bai, Chongyang Liang

Summary: A label-free sensing chip based on porous anodised aluminium (PAA), modified with deactivated Cas9 (dCas9) proteins and synthetic guide RNA (sgRNA), has been developed for the detection of the diffuse large B-cell lymphoma (DLBCL) MYD88(L265P) gene. The sensor utilizes electrochemical ionic current rectification measurement to capture the gene sequence, resulting in a variation in the ion current. The whole sensing process can be completed within 40 minutes without the need for gene amplification.

LAB ON A CHIP (2022)

Add to Collection

Article Oncology

High ETV6 Levels Support Aggressive B Lymphoma Cell Survival and Predict Poor Outcome in Diffuse Large B-Cell Lymphoma Patients

Dario Marino, Marco Pizzi, Iuliia Kotova, Ronny Schmidt, Christoph Schroeder, Vincenza Guzzardo, Ilaria Talli, Edoardo Peroni, Silvia Finotto, Greta Scapinello, Angelo Paolo Dei Tos, Francesco Piazza, Livio Trentin, Vittorina Zagonel, Erich Piovan

Summary: This study identifies two proteins that are important for predicting the survival of patients with diffuse large B-cell lymphoma (DLBCL). Additionally, the expression levels of one of these proteins can predict sensitivity to a specific death-inducing drug, suggesting personalized treatment options. The oncogenic function of ETV6 in DLBCL is also highlighted.

CANCERS (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Outcomes of cardiac diffuse large B-cell lymphoma (DLBCL) in the rituximab era

Taha Al-Juhaishi, Sadeer G. Al-Kindi

Summary: Cardiac diffuse large B-cell lymphoma (cDLBCL) is a rare disease that mostly affects elderly patients. Prognosis is associated with age, disease stage, and insurance status.

INTERNATIONAL JOURNAL OF CARDIOLOGY (2021)

Add to Collection

Article Surgery

TLR-MyD88 signaling blockades inhibit refractory B-1b cell immune responses to transplant-related glycan antigens

Hiroshi Sakai, Yuka Tanaka, Asuka Tanaka, Hideki Ohdan

Summary: The study reveals that MyD88-dependent TLR stimulation enhances downstream factors in the BCR-calcineurin pathway in B-1b cells, providing a novel therapeutic approach for overcoming transplant-related anti-glycan Ab production.

AMERICAN JOURNAL OF TRANSPLANTATION (2021)

Add to Collection

Article Genetics & Heredity

Identification of a 14-Gene Prognostic Signature for Diffuse Large B Cell Lymphoma (DLBCL)

Pengcheng Feng, Hongxia Li, Jinhong Pei, Yan Huang, Guixia Li

Summary: By systematically investigating immune patterns and constructing a prognostic signature with 14 IRGs, researchers have developed a risk assessment tool for DLBCL patients to provide guidance for treatment.

FRONTIERS IN GENETICS (2021)

Add to Collection

Article Chemistry, Medicinal

Design, synthesis and pharmacological evaluation of 2,3-dihydrobenzo-furan IRAK4 inhibitors for the treatment of diffuse large B-cell lymphoma

Yun Chen, Yi Ning, Zhiwei Chen, Yaping Xue, Qingyun Wu, Wenhu Duan, Jian Ding, Jinpei Zhou, Hua Xie, Huibin Zhang

Summary: A series of 2,3-dihydrobenzofuran IRAK4 inhibitors were discovered through structure-based drug design. Compound 22 exhibited strong IRAK4 inhibitory potency and high antiproliferative activity against MYD88 L265P DLBCL cell line. Compound 22 also showed the ability to inhibit IRAK4 signaling pathway activation and induce apoptosis in MYD88 L265P DLBCL cell line.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2023)

Add to Collection

Article Oncology

Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL

Yuan Meng, Biping Deng, Luan Rong, Chuo Li, Weiliang Song, Zhuojun Ling, Jinlong Xu, Jiajia Duan, Zelin Wang, Alex H. Chang, Xiaoming Feng, Xiujuan Xiong, Xiaoli Chen, Jing Pan

Summary: This study demonstrates that short-interval sequential infusions of CAR-T cells can enhance the expansion of prior CAR-T cells in B-NHL patients, leading to improved therapeutic efficacy.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

A bone-based 3D scaffold as an in-vitro model of microenvironment-DLBCL lymphoma cell interaction

Jessica Ceccato, Maria Piazza, Marco Pizzi, Sabrina Manni, Francesco Piazza, Ilaria Caputo, Francesco Cinetto, Lorena Pisoni, Diletta Trojan, Riccardo Scarpa, Renato Zambello, Angelo Paolo Dei Tos, Livio Trentin, Gianpietro Semenzato, Fabrizio Vianello

Summary: This study developed a decellularized bone scaffold 3D model to investigate the role of mesenchymal stromal cells (MSC) and extracellular matrix (ECM) in DLBCL lymphoma cells. The study found that DLBCL cell lines grew in the 3D scaffold and the interaction between cells and the ECM may differ depending on DLBCL subtypes.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Pathology

NGS-based IgH gene rearrangement monitoring predicts relapse and guides maintenance therapy in DLBCL: A case report from indolent lymphoma to aggressive lymphoma

Jie Ji, Yuan Tang, Zhonghe Ke, Beibei Xin, Yu Wu

Summary: This report presents a case study of a 39-year-old female patient with Hashimoto's thyroiditis (HT) who experienced transformation of extranodal marginal zone B-cell lymphoma (ENMZL) of the mucosa-associated lymphoid tissue (MALT) lymphoma to diffuse large B-cell lymphoma (DLBCL). The patient had MALT lymphoma in the thyroid tissue and DLBCL in multiple sites including the ovary, breast, and lymph nodes. Analysis of Ig gene rearrangement and mutation profile showed that the tumor clonotype in the thyroid, ovary, and breast tissues had a shared origin.

PATHOLOGY RESEARCH AND PRACTICE (2023)

Add to Collection

Article Chemistry, Medicinal

Effect of curcumin on regulatory B cells in chronic colitis mice involving TLR/MyD88 signaling pathway

Jie Huang, Tiantian Wu, Youbao Zhong, Jiaqi Huang, Zengping Kang, Bugao Zhou, Haimei Zhao, Duanyong Liu

Summary: Curcumin can regulate the differentiation and function of Breg cells to alleviate chronic colitis by inhibiting the TLR/MyD88 signaling pathway.

PHYTOTHERAPY RESEARCH (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Intracellular osteopontin protects from autoimmunity-driven lymphoma development inhibiting TLR9-MYD88-STAT3 signaling

Celeste Rizzello, Valeria Cancila, Sabina Sangaletti, Laura Botti, Chiara Ratti, Matteo Milani, Matteo Dugo, Francesco Bertoni, Claudio Tripodo, Claudia Chiodoni, Mario P. Colombo

Summary: This study found that in SLE-like syndrome, mice lacking OPN developed splenic lymphomas with higher incidence. Further experiments showed that OPN played an important inhibitory role in autoimmune-driven lymphomagenesis by suppressing the activation of the TLR9-MYD88-STAT3 signaling pathway.

MOLECULAR CANCER (2022)

Add to Collection

Article Oncology

Transformed Lymphoma Is Associated with a Favorable Response to CAR-T-Cell Treatment in DLBCL Patients

Anna Nydegger, Urban Novak, Marie-Noelle Kronig, Myriam Legros, Sacha Zeerleder, Yara Banz, Ulrike Bacher, Thomas Pabst

Summary: This study suggests that patients with transformed/secondary lymphoma have a more favorable course after CAR-T-cell therapy compared to patients with de novo lymphoma.

CANCERS (2021)

Add to Collection

Article Hematology

Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial

Grzegorz S. Nowakowski, Wolfgang Willenbacher, Richard Greil, Thomas S. Larsen, Krish Patel, Ulrich Jaeger, Robert F. Manges, Lorenz Truemper, Hele Everaus, Nagesh Kalakonda, Peter Brown, Judit Meszaros Jorgensen, David Cunningham, Justine Dell'Aringa, Brian Fox, Neus Domper Rubio, Nurgul Kilavuz, Marie-Laure Casadebaig, Oliver Manzke, Javier Munoz

Summary: The study investigated the efficacy of combining durvalumab with traditional R-CHOP therapy or R-2-CHOP therapy in high-risk diffuse large B-cell lymphoma patients. The results showed that while some patients achieved remission with durvalumab + R-CHOP, overall there was no greater benefit compared to traditional therapy, with consistent adverse events.

INTERNATIONAL JOURNAL OF HEMATOLOGY (2022)

Add to Collection

Meeting Abstract Hematology

Relapse Is Uncommon in Patients with Large B-Cell Lymphoma Who Are in Complete Remission at the End of Fixed-Course Glofitamab Treatment

Martin Hutchings, Carmelo Carlo-Stella, Franck Morschhauser, Emmanuel Bachy, Paolo Corradini, Gloria Iacoboni, Cyrus Khan, Krish Patel, Mark Hertzberg, Lorenzo Falchi, Nancy L. Bartlett, Joshua Brody, Linda Lundberg, Yuying Xie, Estefania Mulvihill, Pauline Baumlin, James Relf, Emily Piccione, Kathryn Humphrey, Michael Dickinson

BLOOD (2022)

Add to Collection

Meeting Abstract Hematology

Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Plamotamab Combined with Tafasitamab (Tafa) plus Lenalidomide (Len) Vs Tafa plus Len in Relapsed or Refractory DLBCL

Krish Patel, Youngil Koh, Sabarish Ayyappan, Yasmin Karimi, Izidore S. Lossos, Akil Merchant, Phuong Lee, Jianhua Jin, Raphael Clynes, Jitendra Kanodia, Michael T. Chiarella, Steve Kye, Jean-Marie Michot

BLOOD (2022)

Add to Collection

Meeting Abstract Hematology

Interim Update on the 'Watch' Registry, a Real-World Observational Study Using Clonoseq® to Monitor MRD in Lymphoid Malignancies

Krish Patel, Jakub Svoboda, Bijal D. Shah, Bruce D. Cheson, Georges Azzi, Kashyap Patel, Andrew J. Cowan, Lori Muffly, Heidi Simmons, Mark Schliekelman, Jessica Leonard

BLOOD (2022)

Add to Collection

Meeting Abstract Hematology

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Anthony R. Mato, Jennifer A. Woyach, Jennifer R. Brown, Paolo Ghia, Krish Patel, Toby A. Eyre, Talha Munir, Ewa Lech-Maranda, Nicole Lamanna, Constantine S. Tam, John F. Seymour, Nirav N. Shah, Catherine C. Coombs, Chaitra S. Ujjani, Manish R. Patel, Bita Fakhri, Chan Y. Cheah, Alvaro J. Alencar, Jonathon B. Cohen, James N. Gerson, Ian W. Flinn, Shuo Ma, Deepa Jagadeesh, Joanna M. Rhodes, Francisco Hernandez-Ilizaliturri, Pier Luigi Zinzani, Minna Balbas, Binoj Nair, Paolo B. Abada, Chunxiao Wang, Denise Wang, Donald E. Tsai, William G. Wierda, Wojciech Jurczak

BLOOD (2022)

Add to Collection

Meeting Abstract Hematology

Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenstrom Macroglobulinemia: Results from the Phase 1/2 BRUIN Study

M. Lia Palomba, Manish R. Patel, Toby A. Eyre, Wojciech Jurczak, David John Lewis, Thomas Gastinne, Shuo Ma, Jonathon B. Cohen, Krish Patel, Jennifer R. Brown, Lydia Scarfo, Talha Munir, Ewa Lech-Maranda, Marc Hoffmann, Chaitra S. Ujjani, Bita Fakhri, Michael L. Wang, Koji Izutsu, Hirokazu Nagai, Constantine S. Tam, John F. Seymour, Joanna M. Rhodes, Julie M. Vose, Matthew McKinney, James N. Gerson, Minal A. Barve, Bryone J. Kuss, Youngil Koh, Wei Gao, Amy S. Ruppert, Richard A. Walgren, Donald E. Tsai, Binoj Nair, Katherine Bao, Anthony R. Mato, Chan Y. Cheah

BLOOD (2022)

Add to Collection

Meeting Abstract Hematology

Waveline-001: Updated Results from a Phase 1 Dose Escalation and Cohort Expansion Study of Zilovertamab Vedotin (MK-2140) in Non-Hodgkin Lymphoma

Stephen E. Spurgeon, Matthew Mei, Paul M. Barr, Jacqueline C. Barrientos, Sven de Vos, Richard R. Furman, Krish Patel, Philip A. Thompson, Michael Y. Choi, Avyakta Kallam, Sirou Wang, Uzor C. Ogbu, Akash Nahar, Michael L. Wang

BLOOD (2022)

Add to Collection

Meeting Abstract Hematology

Initial Efficacy and Safety of Acalabrutinib Plus RICE in Transplant Eligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Neil Bailey, Tori Braun, Megumi Bailey, Tenzin Tsomo, Jennie Szeto, Sandra Benitez Kruidenier, Vanessa Dunleavy, Joanna Fesler, Gayle Funk, Sonia Glennie, Judson Hall, Julia Parker, Daniel Egan, Raya Mawad, Carol A. Dean, Suzan Sullivan, Chia Lu, Heidi Hohmann, Jordan Briggs, Krish Patel

BLOOD (2022)

Add to Collection

Meeting Abstract Hematology

NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton's Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies

Anthony R. Mato, William G. Wierda, Weiyun Z. Ai, Ian W. Flinn, Michael Tees, Manish R. Patel, Krish Patel, Susan O'Brien, David A. Bond, Lindsey E. Roeker, Tanya Siddiqi, Michael L. Wang, Clare Sun, Omar Abdel-Wahab, Amanda Schwab, May Tan, Erin Meredith, Melissa A. Gessner, Su Young Kim, Adrian Wiestner, Alexey Danilov

BLOOD (2022)

Add to Collection

Meeting Abstract Hematology

Outcomes of Therapies and Resistance Mutations Following Non-Covalent Bruton's Tyrosine Kinase Inhibitor Treatment for Patients with Chronic Lymphocytic Leukemia and Richter Transformation

Meghan C. Thompson, Catherine C. Coombs, Lindsey E. Roeker, Jeffrey L. Jensen, Nirav N. Shah, Thomas Luo, Krish Patel, Neil Bailey, Bita Fakhri, Toby A. Eyre, Paola Ghione, Joanna M. Rhodes, Andrew D. Zelenetz, Justin Taylor, Maria Lia Palomba, Kendall Meyer, Danielle Rao, Yehudit Fox, Julia H. Aronson, Sarah Court, Omar Abdel-Wahab, Anthony R. Mato

BLOOD (2022)

Add to Collection

Meeting Abstract Hematology

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Michael L. Wang, Nirav N. Shah, Wojciech Jurczak, Pier Luigi Zinzani, Toby A. Eyre, Chan Y. Cheah, Chaitra S. Ujjani, Youngil Koh, Koji Izutsu, James N. Gerson, Ian W. Flinn, Benoit Tessoulin, Alvaro J. Alencar, Shuo Ma, Ewa Lech-Maranda, Joanna M. Rhodes, Krish Patel, Jennifer A. Woyach, Nicole Lamanna, Yucai Wang, Constantine S. Tam, John F. Seymour, Talha Munir, Hirokazu Nagai, Francisco Hernandez-Ilizaliturri, Anita Kumar, Andrew D. Zelenetz, Preetesh Jain, Binoj Nair, Donald E. Tsai, Minna Balbas, Richard A. Walgren, Paolo B. Abada, Chunxiao Wang, Junjie Zhao, Anthony R. Mato

BLOOD (2022)

Add to Collection

Article Oncology

Treatment selection for patients with relapsed or refractory follicular lymphoma

Alan Z. Skarbnik, Krish Patel

Summary: Follicular lymphoma (FL) is a common lymphoma with a variable clinical course. The response to treatment decreases with each line of therapy, and poor survival outcomes are associated with disease progression within 24 months of initial treatment. Although rituximab-based regimens are preferred for early lines of treatment, there is no clear standard of care for third-line treatment or later.

FRONTIERS IN ONCOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia

Anthony R. Mato, Jennifer A. Woyach, Jennifer R. Brown, Paolo Ghia, Krish Patel, Toby A. Eyre, Talha Munir, Ewa Lech-Maranda, Nicole Lamanna, Constantine S. Tam, Nirav N. Shah, Catherine C. Coombs, Chaitra S. Ujjani, Bita Fakhri, Chan Y. Cheah, Manish R. Patel, Alvaro J. Alencar, Jonathon B. Cohen, James N. Gerson, Ian W. Flinn, Shuo Ma, Deepa Jagadeesh, Joanna M. Rhodes, Francisco Hernandez-Ilizaliturri, Pier L. Zinzani, John F. Seymour, Minna Balbas, Binoj Nair, Paolo Abada, Chunxiao Wang, Amy S. Ruppert, Denise Wang, Donald E. Tsai, William G. Wierda, Wojciech Jurczak

Summary: Pirtobrutinib, a noncovalent BTK inhibitor, showed efficacy in patients with CLL or SLL who had previously received covalent BTK inhibitor treatment. The most common adverse events were infections, bleeding, and neutropenia.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Meeting Abstract Hematology

Phase 1/2 Study of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results with >4 Years of Follow-up

Richard R. Furman, William G. Wierda, Anna Schuh, Piers Em Patten, Jorge M. Chaves, Jennifer R. Brown, Talha Munir, Peter Martin, Farrukh T. Awan, Deborah M. Stephens, Paolo Ghia, Jacqueline C. Barrientos, Krish Patel, Jennifer A. Woyach, Anna Butturini, Marianne de Borja, Min Hui Wang, Susan O'Brien, John C. Byrd

BLOOD (2022)

Add to Collection

Meeting Abstract Oncology

Axicabtagene ciloleucel (axi-cel) in combination with rituximab (Rtx) for the treatment (Tx) of refractory large B-cell lymphoma (R-LBCL): Outcomes of the phase 2 ZUMA-14 study.

Paolo Strati, Lori Ann Leslie, Parveen Shiraz, L. Elizabeth Budde, Olalekan O. Oluwole, Matthew Ulrickson, Aravind Ramakrishnan, Jennifer Sun, Rhine Shen, Justyna Kanska, Peter McCroskery, Jinghui Dong, Marco Andreas Schupp, Hairong Xu, Krish Patel

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.